Puma and CANBridge cancel licensing deal for $20m

Los Angeles company Puma Biotechnology and Beijing-based CANBridge Pharmaceuticals have cancelled a 2018 licensing deal which gave the latter exclusive rights to a breast cancer drug in China.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AstraZeneca sues Dr Reddy's over breast cancer drug

14 February 2017 AstraZeneca has filed a patent infringement claim against Dr Reddy's Laboratories over the drug Faslodex (fulvestrant) intramuscular injection, a treatment for breast cancer.

Americas

Genentech adds to breast cancer pipeline with Seragon buyout

2 July 2014 Genentech has entered into an agreement to buy Seragon, a San Diego-based biotech company that specialises in developing treatments that target hormone-driven cancers, for up to $1.7 billion.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Puma and CANBridge cancel licensing deal for $20m

More on this story

Editor's picks

Editor's picks

More features